alexa Glucagon-Like Peptide-1 Analogues and Anxiety and Abnor
ISSN: 2155-6156

Journal of Diabetes & Metabolism
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Case Report

Glucagon-Like Peptide-1 Analogues and Anxiety and Abnormal Eating Behaviours in Type 2 Diabetes: A Case Report

Anne Marie Doherty1*, Rosarie Atkinson2 and Mark Chamley3

1Consultant Liaison Psychiatrist, Diabetes Department, King’s College Hospital, London, UK

2Diabetes Specialist Nurse, Lambeth Diabetes Intermediate Community Team, Crown Dale Medical Centre, UK

3General Practitioner Lead, Lambeth Diabetes Intermediate Community Team, Crown Dale Medical Centre, UK

*Corresponding Author:
Anne Marie Doherty
Diabetes Department, King’s College Hospital
London, SE5 9RS, United Kingdom
Tel: +44 (0)203 299 1350
Fax: +44 (0)203 299 1350
E-mail: [email protected]

Received date: May 05, 2014; Accepted date: May 29, 2014; Published date: June 04, 2014

Citation: Doherty AM, Atkinson R, Chamley M (2014) Glucagon-Like Peptide-1 Analogues and Anxiety and Abnormal Eating Behaviours in Type 2 Diabetes: A Case Report. J Diabetes Metab 5:381. doi: 10.4172/2155-6156.1000381

Copyright: © 2014 Doherty AM et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Psychological and psychiatric problems are common in diabetes. Glucagon-like peptide-1 (GLP-1) analogues are effective in the management of type 2 diabetes as second or third-line treatment, and are thought to have a central effect on appetite regulation. There is little evidence regarding the effect of GLP-1 analogues on anxiety. This is a case report of a patient with type 2 diabetes, obesity, anxiety and disordered eating who was commenced on Liraglutide, a glucagon-like peptide-1 (GLP-1) analogue. This patient reported, in addition to improved glycaemic control, a marked improvement in the anxiety which had been present all her life, and had driven her binge eating. This anxiety had persisted despite anxiolytic medications and cognitive behaviour therapy. Any medication which could have a positive effect on anxiety and diabetes both would be valuable. Glucagon like peptide analogues may have a role in the management of co-morbid anxiety and type 2 diabetes. Further research is required into this area.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords